Key result
In patients with HFrEF, 39% did not receive optimal doses of β-blockers, and higher equivalent dosing was independently associated with a reduction in mortality.
Why the study?
Higher doses of beta-blockers in HFrEF are associated with better outcomes, but data on the proportion receiving optimized doses and factors associated with suboptimal dosing were needed.
Does optimized dosing of β-blockers improve survival in patients with HFrEF compared to suboptimal dosing?
Cohort (n=390)
Yes
Does optimized dosing of β-blockers improve survival in patients with HFrEF compared to suboptimal dosing?
Answers are grounded in this paper and cite their sources.
A significant proportion of HFrEF patients receive suboptimal doses of beta-blockers without clear contraindications, which is associated with reduced survival.
BACKGROUND: The evidence base for the benefits of β-blockers in heart failure with reduced ejection fraction (HFrEF) suggests that higher doses are associated with better outcomes. OBJECTIVES: The aim of this study was to report the proportion of patients receiving optimized doses of β-blockers, outcomes, and factors associated with suboptimal dosing. METHODS: This was a prospective cohort study of 390 patients with HFrEF undergoing clinical and echocardiography assessment at baseline and at 1 year. RESULTS: Two hundred thirty-seven patients (61%) were receiving optimized doses (≥5-mg/d bisoprolol equivalent), 72 (18%) could not be up-titrated (because of heart rate < 60 beats/min or systolic blood pressure <100 mm Hg), and the remaining 81 (21%) should have been. Survival was similarly reduced in those who could not and should have been receiving 5 mg/d or greater, and patient factors did not explain the failure to attain optimized dosing. CONCLUSIONS: Many patients with HFrEF are not receiving optimal dosing of β-blockers, and in around half, there was no clear contraindication in terms of heart rate or blood pressure.
No takes yet. Share an insight, caveat, or question.
McGinlay et al. (2021) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=390). Optimized dosing of β-blockers vs. Suboptimal dosing (<5-mg/d bisoprolol equivalent) was evaluated on All-cause mortality (HR 0.96, 95% CI 0.92-1.00, p=0.029). In patients with HFrEF, 39% did not receive optimal doses of β-blockers, and higher equivalent dosing was independently associated with a reduction in mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: